Latest Breaking News On - Bo cumbo - Page 1 : vimarsana.com

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

Solid Biosciences' SGT-003 receives rare pediatric disease designation

Solid Biosciences has received the US FDA rare pediatric disease designation for its gene therapy candidate for Duchenne, SGT-003.

Solid Biosciences (SLDB) Receives FDA Rare Pediatric Disease Designation for SGT-003

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Solid Biosciences to Participate at Cantor's Virtual Muscular Dystrophy Symposium

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

Solid Biosciences Provides Fourth Quarter and Full-Year

Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003

– Next-generation gene transfer therapy to treat Duchenne receives FDA Fast Track Designation – CHARLESTOWN, Mass., Dec. 07, 2023 -- Solid Biosciences Inc. , a life sciences company...

What's Going On With Solid Biosciences Stock Today? - Solid Biosciences (NASDAQ:SLDB)

Solid Biosciences Inc. (NASDAQ: SLDB) shares traded higher on Thursday. The company announced that it received Fast Track Designation from the U.S.

Solid Up 27% On Receiving FDA IND For SGT-003

Shares of Solid Biosciences Inc. (SLDB) are up 27% on Wednesday following the announcement of FDA clearance of its Investigational New Drug (IND) application for SGT-003, which is the company's latest gene therapy candidate for Duchenne Muscular Dystrophy (Duchenne).